FY2030 Earnings Forecast for CHRS Issued By HC Wainwright

Coherus Oncology, Inc. (NASDAQ:CHRS – Free Report) – Stock analysts at HC Wainwright lowered their FY2030 earnings estimates for shares of Coherus Oncology in a report issued on Tuesday, November 10th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings of $0.15 per share for the year, down from their previous forecast of $0.19. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Coherus Oncology’s current full-year earnings is ($0.86) per share.

A number of other equities analysts have also recently issued reports on the stock. Wall Street Zen cut shares of Coherus Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, November 14th. Weiss Ratings downgraded Coherus Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, November 10th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Read Our Latest Report on CHRS

Coherus Oncology Trading Down 5.2%

CHRS opened at $0.37 on Thursday. Coherus Oncology has a 1-year low of $0.36 and a 1-year high of $2.62. The company has a current ratio of 1.51, a quick ratio of 1.45 and a debt-to-equity ratio of 2.08. The company has a market cap of $57.13 million, a P/E ratio of -0.38 and a beta of 1.03. The company has a fifty day moving average price of $0.97 and a two-hundred day moving average price of $1.43.

Coherus Oncology (NASDAQ:CHRS – Get Free Report) last issued its earnings results on Monday, November 9th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.03). The company had revenue of $14.27 million for the quarter, compared to the consensus estimate of $15.90 million. Coherus Oncology had a negative return on equity of 274.46% and a negative net margin of 253.43%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Coherus Oncology in the 2nd quarter worth about $16,805,000. Goldman Sachs Group Inc. boosted its stake in shares of Coherus Oncology by 231.4% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,995,469 shares of the biotechnology company’s stock worth $2,415,000 after buying an additional 1,393,394 shares during the last quarter. Sei Investments Co. boosted its stake in shares of Coherus Oncology by 492.2% in the 1st quarter. Sei Investments Co. now owns 453,763 shares of the biotechnology company’s stock worth $767,000 after buying an additional 377,134 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Coherus Oncology by 140.5% in the 1st quarter. Renaissance Technologies LLC now owns 331,700 shares of the biotechnology company’s stock worth $561,000 after buying an additional 193,800 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Coherus Oncology by 190.2% in the first quarter. Bank of America Corp DE now owns 324,133 shares of the biotechnology company’s stock valued at $548,000 after acquiring an additional 212,430 shares in the last quarter. Institutional investors own 72.82% of the company’s stock.

More Coherus Oncology News

Here’s some of the latest news about CHRS:

  • Negative Sentiment: HC Wainwright trimmed estimates for FY2026–FY2029, including FY2026 EPS from ($0.84) to ($0.89), FY2027 from ($0.63) to ($0.68), FY2028 from ($0.48) to ($0.54), and FY2029 from ($0.19) to ($0.26). It also lowered estimates for Q4 2026 and each quarter of 2027. These revisions point to greater expected losses in the near term and beyond. MarketBeat coverage
  • Neutral Sentiment: Despite lowering its forecasts, HC Wainwright kept its Buy rating on CHRS. MarketBeat coverage

About Coherus Oncology

(Get Free Report)

Coherus Oncology, formerly Coherus BioSciences, is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its portfolio includes LOQTORZI (toripalimab-tpzi), an immune checkpoint inhibitor that targets PD-1 and is approved in the United States for certain patients with nasopharyngeal cancer. The company is also advancing a pipeline of investigational immuno-oncology medicines. Coherus historically built its business around biosimilar medicines before shifting its focus to oncology.

Read More

Earnings History and Estimates for Coherus Oncology (NASDAQ:CHRS)

Receive News & Ratings for Coherus Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Oncology and related companies with MarketBeat.com's FREE daily email newsletter.